The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases.
 
Michael J. Morris
Consulting or Advisory Role - Astellas Pharma; Bayer; Millennium; Progenics
Research Funding - Agensys (Inst); Bayer (Inst); Janssen Oncology (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - fujifilm
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; Bayer; Celgene; Janssen; Pierre Fabre; Roche; Sanofi
Travel, Accommodations, Expenses - Bayer; Sanofi
 
Christopher Sweeney
Stock and Other Ownership Interests - BIND Biosciences; Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BIND Biosciences; Genentech/Roche; Janssen Biotech; Sanofi
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Janssen Biotech (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Karim Fizazi
Honoraria - Amgen; Astellas Pharma; Janssen; Sanofi; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; ESSA; Janssen; Novartis; Orion; Roche; Sanofi
 
Charles J. Ryan
Honoraria - Astellas Pharma; Janssen
Consulting or Advisory Role - AstraZeneca; Bayer; Ferring
Speakers' Bureau - Janssen
Research Funding - Karyopharm Therapeutics (Inst)
 
Daniel H. Shevrin
Speakers' Bureau - Astellas Pharma; Bayer
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Consulting or Advisory Role - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
John Reeves
Employment - Bayer
 
Kumari Chandrawansa
Employment - Bayer
Stock and Other Ownership Interests - Bayer; Lilly
 
Martin Kornacker
Employment - Bayer
Stock and Other Ownership Interests - Bayer
 
Celestia S. Higano
Employment - Cell Therapeutics (I)
Leadership - Cell Therapeutics (I)
Stock and Other Ownership Interests - Cell Therapeutics (I)
Consulting or Advisory Role - AbbVie; Bayer; BHR Pharma; Dendreon; Ferring; Genentech; Johnson & Johnson; Medivation; Orion; Pfizer; Sanofi
Research Funding - Algeta/Bayer (Inst); Aragon Pharmaceuticals (Inst); AstraZeneca (Inst); Dendreon (Inst); Emergent BioSolutions (Inst); Exelixis (Inst); Genentech (Inst); Medivation (Inst); Millennium (Inst); Oncogenex (Inst); Sanofi (Inst); Teva (Inst)
Travel, Accommodations, Expenses - AbbVie; Amgen; Astellas Pharma; Bayer; Dendreon; Ferring; Genentech; Johnson & Johnson; Medivation; Ockham; Orion; Pfizer; Sanofi; Teva